JKAP serves as a potential biomarker for the evaluation of inflammatory condition, disease activity, and treatment response to TNF inhibitor in ankylosing spondylitis patients.

Zhou, Xianjie; Li, Mingwu

Zhou, Xianjie; Li, Mingwu.

Afiliação

Zhou X; Department of Orthopedics, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, China.
Li M; Department of Orthopedics, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, China.

Mod Rheumatol ; 32(3): 613-618, 2022 Apr 18.

Article em En | MEDLINE | ID: mdl-34918117

Assuntos

Fosfoproteínas Fosfatases/análise; Espondilite Anquilosante; Inibidores do Fator de Necrose Tumoral; Adalimumab/uso terapêutico; Biomarcadores; Humanos; Espondilite Anquilosante/diagnóstico; Espondilite Anquilosante/tratamento farmacológico; Resultado do Tratamento; Inibidores do Fator de Necrose Tumoral/uso terapêutico; Fator de Necrose Tumoral alfa

Palavras-chave

Assessment in SpondyloArthritis international Society 40 response; Jun N-terminal kinase pathway-associated phosphatase; TNF inhibitor; ankylosing spondylitis; disease activity

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Espondilite Anquilosante / Fosfoproteínas Fosfatases / Inibidores do Fator de Necrose Tumoral Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Mod Rheumatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google